Improved CAR-T cell targeting of cancer
Description of the granted funding
Chimeric antigen receptor (CAR)-T cell therapy is a promising new approach for treating cancer, where an engineered CAR molecule is introduced into patient's immune cells to direct them to destroy cancer cells. CAR-T cell therapy has been very successful in treating leukemias and lymphomas. However, most cancers lack any truly cancer-specific determinants, and it has been difficult to create CAR-T cells that would efficiently kill cancer without attacking healthy tissues. Our laboratory has developed a new and highly tunable targeting technology based on a small protein module, known as the SH3 domain. We have already shown that using modified SH3 domains it is possible to create CAR-T cells that can sense even relative differences between cancer and normal cell surface structures. Here we propose a series of experiments designed to exploit this opportunity in order to develop potent but safe CAR-T cell therapies for ovarian and other cancers that have remained difficult to treat.
Show moreStarting year
2020
End year
2024
Granted funding
Other information
Funding decision number
331787
Fields of science
Biomedicine
Research fields
Biolääketieteet
Identified topics
cancer